Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

People who buy the stock today are thus exposed to a high risk of their shares getting diluted. That's in addition to the ...

The announcement about its new trial sent shares up by 70% and is good news for big pharma partner GSK who will take over ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its ...

Sep. 25, 2024 — Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to the new results of an ...

Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential ...

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...